Perampanel as first add-on antiseizure medication: Italian consensus clinical practice statements

Paolo Bonanni1*, Antonio Gambardella2*, Paolo Tinuper3,4*, Benedetto Acone5, Emilio Perucca6,7* and Giangennaro Coppola8

Abstract
Background: When use of a single antiseizure medication (ASM) fails to induce seizure remission, add-on therapy is justified. Perampanel (PER) is approved in Europe as adjunctive therapy for focal, focal to bilateral tonic-clonic seizures and generalized tonic-clonic seizures. Aim of the study was to establish whether PER is suitable for first add-on use.

Methods: A Delphi methodology was adopted to assess consensus on a list of 39 statements produced by an Expert Board of 5 epileptologists. Using an iterative process, statements were finalized by a Delphi Panel of 84 Italian pediatric and adult neurologists. Each statement was rated anonymously to determine level of agreement on a 9-point Likert scale. Consensus was established as agreement by at least 80% of the panelists. The relevance of each statement was also assessed on a 3-point scale.

Results: Consensus was achieved for 37 statements. Characteristics of PER considered to justify its use as first add-on include evidence of a positive impact on quality of life based on long term retention data, efficacy, tolerability, and ease of use; no worsening of cognitive functions and sleep quality; a low potential for drug interactions; a unique mechanism of action. Potential unfavorable factors are the need for a relatively slow dose titration; the potential occurrence of behavioral adverse effects; lack of information on safety when used in pregnancy; limited access to plasma PER levels.

Conclusion: Perampanel has many features which justify its use as a first add-on. Choice of an ASM as first add-on should be tailored to individual characteristics.

Keywords: Perampanel, Epilepsy, Delphi procedure, Antiepileptic drugs, Adjunctive therapy

Background
In about 50% of patients, the antiseizure medication (ASM) used initially fails to induce sustained seizure remission [1]. In these patients, management options involve use of an alternative monotherapy or a combination therapy. There is no evidence that either strategy is superior to the other [2, 3].

When a first add-on strategy is preferred, the selection of the ASM is not simple. When all factors that need to be taken into account are considered [4], it is clear that none of the available ASMs is ideal for use as a first add-on in all patients. Yet, it is important for physicians to be aware of the characteristics of each ASM, and of the criteria to be used in deciding to what extent such characteristics should favor or discourage first add-on use in individual cases.

*Correspondence: paolo.bonanni@lanostrafamiglia.it
1 IRCCS Eugenio Medea Scientific Institute, Epilepsy Unit, Conegliano, Via Costa Alta 37, 31015 Conegliano, TV, Italy
Full list of author information is available at the end of the article
In this article, we used a Delphi approach to produce a consensus document outlining to what extent perampanel (PER) meets the characteristics that would favor its first add-on use. Perampanel is approved in Europe as adjunctive therapy of focal and focal to bilateral tonic-clonic seizures (FBTCS) in patients aged ≥4 years, and as adjunctive treatment of generalized tonic-clonic seizures (GTCS) in patients aged ≥7 years with idiopathic generalized epilepsy (IGE).

Methods
The Delphi process is a well-established methodological tool which is used to assess and integrate the opinions of experts in areas where univocal evidence from well design studies is unavailable [5]. The procedure used to produce the present document has been described in detail in a previous publication [4]. In short, an Expert Board of 5 epileptologists produced initially a list of 39 statements relevant to the aims of the work. Using an iterative process, statements were finalized by a Delphi Panel of 84 Italian pediatric and adult neurologists (Appendix). Each statement was rated anonymously to determine level of agreement on a 9-point Likert scale. Consensus was established as agreement by at least 80% of panelists. The relevance of each statement was also assessed on a 3-point scale.

Results
Seventy-four of the 84 members of the Delphi Panel (87%) completed all rounds of the rating procedures. Thirty six of the 39 initial statements reached consensus in the first round. The remaining three statements were modified based on feedback received in the first round, and, of these, one achieved consensus later in the process. Therefore, consensus was ultimately reached for 37 (95%) of the 39 statements. Clinical relevance received a mean rating above 2 (on 3-point scale) for all of the statements when selecting an ASM as first add-on [4,6–8].

Statements related to efficacy

There was consensus among Panel members that PER is effective against focal and GTCS and does not worsen other types of seizures, such as absence or myoclonic seizures.

In randomized double-blind trials, responder rates recorded in adolescents and adults have been found to be significantly greater with PER than with placebo for focal seizures, FBTCS, and GTCS [9,10,12]. More recently, Brandt et al. [19] in a post hoc analysis found that PER does not exacerbate absence seizures or myoclonic jerks in patients with IGE. In particular, the number of patients who developed "de novo" myoclonic and/or absence seizures during PER treatment was the same as in the placebo-treated patients.

Of note, the efficacy and safety profile of PER reported during long-term follow-up studies is similar to that observed in double-blind, phase III studies [11,13]. A recent global, multicenter, open-label, single-arm study provided evidence for PER being also safe and effective in the adjunctive therapy of focal seizures, focal to FBTCS and GTCS in children age 4 to <12 years [14].

There was consensus that PER may be useful when there is uncertainty on whether seizures are focal or generalized.

Because PER is effective against focal as well as GTCS, its use may be considered for patients who experienced one or more tonic-clonic seizures that could not be readily classified as being of either focal or generalized onset [20]. Such diagnostic uncertainty is especially common in childhood epilepsies [21]. The feasibility of using a broad-spectrum ASM in this situation, however, should not lead to neglect further investigations to diagnose the correct seizure type and syndrome.

There was consensus that PER can be effective and well tolerated when used either early or late as add-on therapy, even at low doses.

The results of a post-hoc analysis of Phase III trials indicate that adjunctive treatment with PER is associated with greater efficacy in patients who are taking fewer concomitant ASMs [22]. A pooled post hoc analysis of four randomized studies [23] also showed that adjunctive therapy with PER can be efficacious at low doses (4 mg/day). Of note, the improvement in seizure control at a dose of 4 mg/day was greater in patients not receiving enzyme inducing
ASMs, whereas the occurrence of adverse effects (AEs) at that dose was similar in patients on and off enzyme inducers [23]. Recent multicenter open-label prospective trials reported that use of PER as first add-on at a median dose of 6 mg/day was associated with improved control of focal seizures, with or without evolution to FBTCS, as well as GTCS [15, 16].

Statements related to safety and tolerability

There was consensus that PER has a favorable short- and long-term safety and tolerability profile. There was also consensus that, like other ASMs, PER can cause dose-related AEs, the most frequent of which are dizziness, somnolence, headache, fatigue, and irritability, and that these dose-related AEs, especially those affecting the central nervous system (CNS), occur more commonly in the first weeks and tend to decrease over time with the continuation of therapy. The Panel also agreed that PER tolerability is improved when fewer concomitant ASMs are used, and when PER is administered at low doses and with a slow titration.

Post hoc analyses of data from pooled Phase III studies have shown that most AEs of PER occur during the titration phase and tend to subside within a few weeks [24]. A post-hoc analysis of data from Phase III studies has also suggested that tolerability is improved when PER is used as an early add-on treatment [22]. More recent prospective or retrospective studies have reported that, when PER is prescribed as first add-on, the frequency of AEs is halved, especially when low doses (≤ 6 mg) and a slow titration (2 mg/day every > 2 weeks) are used [15, 16].

There was consensus that a decision to use PER should take into consideration any comorbidities present at baseline, as for other ASMs. In consideration of PER’s behavioral and psychiatric tolerability profile (mainly irritability), there was consensus about the need to carefully evaluate whether PER is indicated in patients who present with these problems at baseline or in their medical history, and to monitor clinical response should the drug be prescribed in these patients. There was also consensus that when PER is used as first add-on therapy, it may be possible to reduce the dose of concomitant ASMs in order to optimize tolerability.

The retrospective Fydata study has shown that patients with prior psychiatric comorbidities are more likely to experience psychiatric AEs with PER [25]. However, Hasegawa and Tohyama [26] in another retrospective study reported that PER may either aggravate or ameliorate psychiatric and behavioral symptoms, and that, in particular, improvement may occur in seizure-free patients. In a cohort of patients with drug-resistant focal epilepsy, PER did not increase the baseline level of irritability, depression, or anxiety [27]. Additionally, many real-life retrospective and prospective studies have indicated that use of slow titration schedules (2 mg/3–4 weeks) and low doses are associated with a lower risk of psychiatric AEs, especially when PER is used as first add-on [15, 16, 25].

The Panel agreed that, in either adolescents or adults, significant AEs of PER on cognitive functions have not been demonstrated in the short- and medium-term.

The evidence supporting this statement comes from a double blind, randomised study [28] and 4 observational prospective studies [14, 29–31]. ASM-induced cognitive AEs are one of the main detrimental factors for the quality of life of people with epilepsy. The favorable cognitive profile of PER is, therefore, important in this regard.

There was consensus that, although sleepiness is an AE associated with the use of PER, assessment of sleep through specific tests has shown that PER does not worsen daytime sleepiness and the quality of night sleep in most patients.

The data published by Rocamora et al. [32] suggest that PER can improve the quality of sleep by having a favorable effect on several sleep parameters, without worsening daytime sleepiness. Sleep disorders in patients with epilepsy have a high prevalence and poor sleep quality or duration can worsen seizure control and, consequently, quality of life [32].

There was consensus that PER does not affect adversely cardiac electrophysiology.

A Phase I thorough QT study and a pooled analysis of 3 Phase III studies have shown no evidence of prolonged QT interval duration with PER treatment [33].

There was consensus that there are currently no data on the safety of PER in pregnancy, particularly with regard to seizure control and possible AEs on the offspring.

Following the completion of the Delphi Panel, a report of 96 pregnancies exposed to PER has been published [34]. However, the data presented are insufficient to make any meaningful estimate of potential risks for the mother or the offspring.
Concomitant ASMs and drug interactions

Perampanel is indicated for add-on therapy. PER is metabolised in the liver and is subject to enzyme induction. There was consensus that, when adding PER to a pre-existing monotherapy, it is worth considering whether or not an inducer is present because a higher dose of PER may be needed.

A number of enzyme inducing ASMs (carbamazepine, oxcarbazepine and phenytoin) have been found to stimulate PER metabolism and to reduce the plasma exposure to PER without affecting the relationship between plasma PER concentration and clinical response [35, 36]. In a post hoc analysis of randomized trials, seizure reduction at PER doses of 8 and 12 mg/day was significantly greater in patients receiving non-enzyme inducing ASMs than in patients receiving enzyme inducers [37]. The incidence of some AEs, however, was also greater in patients on non-enzyme inducing ASMs. For patients taking enzyme inducing ASMs, any decrease in efficacy due to reduced exposure could be compensated for by increasing the dose of PER [37, 38]. According to European and U.S. prescribing information, however, a dose of 12 mg/day should not be exceeded even in the presence of enzyme inducers, because there is insufficient information on the use of higher doses [39, 40].

The Panel agreed that there is no evidence that the risk of AEs is increased when PER is combined with specific ASMs or ASM classes. There was also consensus that to optimize PER tolerability it may be possible to reduce the dosage of concomitant ASMs.

In some real life studies, the introduction of PER has permitted to simplify the ASM regimen and, in some cases, to convert patients to PER monotherapy [15, 41].

The Panel agreed that PER has a limited number of drug interactions, generally of modest clinical significance. No drug interactions leading to a worsening of the tolerability of PER have been reported to date.

As discussed above, concomitantly administered carbamazepine, phenytoin and oxcarbazepine decrease plasma PER concentrations to an extent that can be clinically significant. Moreover, PER has been found to cause a modest (< 10%) decrease in the plasma concentration of carbamazepine, clobazam, lamotrigine, and valproic acid [39], but these interactions are not expected to be of clinical significance.

At a dose of 12 mg/day, but not 4 or 8 mg/day, PER decreases by about 40% the plasma concentration of levonorgestrel, potentially resulting in contraceptive failure [39].

Mechanism of action

There was consensus that PER has a unique mechanism of action, which is complementary to that of other ASMs currently on the market.

Perampanel is a noncompetitive selective antagonist of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor. AMPA receptors mediate postsynaptic responses to glutamate, the primary excitatory neurotransmitter in the CNS, and are thought to play a crucial role in the generation and spread of epileptic activity [42].

When selecting an ASM for adjunctive therapy, the mechanism of action is a potentially important consideration, especially when adding a first add-on drug [4]. Evidence from preclinical and clinical studies suggests that combinations of ASMs with different mechanisms lead to improved outcomes compared with combinations of ASMs acting by the same mechanism [43–46].

Statements related to adherence issues

There was consensus that PER shows several properties facilitating a good adherence, i.e. a long plasma half-life that allows once daily administration, a simple dosing schedule (one tablet for each dosing level), and the convenience of single dosing at bedtime. The statement that regular compilation of the therapeutic plan can improve therapeutic adherence failed to reach the threshold for consensus among Panel members.

Over one-third of patients with epilepsy are non-adherent to the prescribed treatment regimen, and suboptimal adherence is an important cause of persisting seizures [47], as well as a risk factor for emergency department visits, hospital admissions, injuries, and even mortality [48], possibly due to SUDEP [49]. ASMs that need to be taken less frequently have been consistently associated with better adherence [50]. The therapeutic plan is a requirement set by Italian Health Authorities for certain medicines. It requires prescriptions to be registered in a file which, in the case of PER, must include the patient’s personal data and the eligibility criteria for the correct prescription of the medication as stated by the summary of product characteristics. However, it is not a specific purpose of the therapeutic plan to improve adherence to therapy.

Ease of use of the medication and monitoring procedures

There was consensus that PER is associated with several factors associated with ease of use, such as a simple one-tablet once daily dosing regimen, avail-
ability of different oral formulations, effectiveness at low doses in some patients, and no requirement for repeated routine blood chemistry or laboratory investigations in most patients. The Panel also agreed that, should therapeutic drug monitoring be desirable, measurements of plasma PER levels are not widely accessible.

Overall, PER has several characteristics considered to be desirable for a first add-on use ASM, including a simple once-daily dosing regimen, the availability of both liquid and solid oral dosage forms, and no need for intrusive monitoring [4]. There are, however, other desirable properties that are not met by PER, such as the need for relatively slow titration, the lack of parenteral formulations, and the lack of wide access to services for measuring plasma PER levels, which could aid in assessing adherence [4].

Peculiarities to the Italian setting

The Panel agreed that distribution through the DPC channel (i.e. the acquisition and distribution of medicines to pharmacies handled by local health authorities) guarantees PER availability and avoids medication shortage problems. The Panel also agreed that the pricing system for PER in Italy guarantees the same cost to the national health service irrespective of the prescribed daily dose. There was also consensus that the distribution of drugs such as PER, that are included in the PHT formulary (hospital-district level formulary), guarantees greater cost-effectiveness for the health service compared to non-PHT drugs, which mainly use the traditional distribution channel. However, there was no consensus that compilation of the therapeutic plan can improve the appropriateness of PER prescribing.

The statements listed above reflect measures that are in place to facilitate access to, and a more cost-effective use of medications, such as PER, which are distributed via the PER-PHT channel. The therapeutic plan is a requirement set by Italian Health Authorities. Although one purpose of the therapeutic plan is to facilitate the appropriate use of medicines, the statement that prescribing appropriateness is improved by the therapeutic plan just failed to reach the threshold for consensus (Supplementary Table 3).

Discussion

In a previous document, we defined the ideal pharmacological and clinical characteristics which favor utilization of an ASM as first add-on in patients with epilepsy unresponsive to monotherapy [4]. We have now applied a Delphi procedure to finalize a consensus document to determine to what extent PER meets such characteristics.

The Panel agreed that the efficacy of PER as adjunctive treatment of focal seizures and GTCS has been clearly demonstrated, and that there is no evidence for PER causing a worsening of other seizure types such as absence or myoclonic seizures. Because of this, PER was considered to provide an option for the adjunctive treatment of patients in whom there is uncertainty on whether seizure onset is focal or generalized. There was also consensus that PER can be effective at low doses and is generally well tolerated when used either early or late in the treatment algorithm. Most importantly, there was consensus that PER's favorable short- and long-term retention demonstrated in clinical trials and observational studies, together with its efficacy, tolerability, safety and ease of use, are indicative of a positive impact on quality of life, and are consistent with the use of PER as first add-on medication. Additional desirable characteristics of PER which are relevant to first add-on use include a simple, one-tablet once daily dosing scheme facilitating adherence; availability of solid and liquid oral formulations; evidence for a positive effect on the quality of night sleep; evidence of lack of negative impact on cognitive functions; and no need for intrusive safety monitoring procedures. On the other hand, properties which are not ideal for first add-on use include the need for relatively slow dose titration; the potential occurrence of behavioral and psychiatric AEs, particularly in patients with a history of such problems; lack of information on maternal and fetal safety when used in pregnancy; and limited availability of services for measuring plasma PER levels.

There was also agreement that PER shows a better tolerability when it is used in combination with fewer ASMs, at low doses such as 4 and 6 mg/day and with a slow titration. A desirable feature of PER which is relevant to add-on use is its unique mechanism, which facilitates use in combination with any ASM. PER also has a low interaction potential, although its susceptibility to enzyme induction and the possible need for higher doses in patients comedicated with certain enzyme inducing ASMs was acknowledged.

Conclusions

Based on the points highlighted in the present consensus paper, it can be concluded that PER shows many characteristics favoring first add-on use in patients with focal or GTCS not adequately controlled on monotherapy. While PER may represent a valuable option for such patients, it should be emphasized that ultimately the choice of the ASM to be used preferentially as first add-on should be tailored to individual characteristics.
Appendix

List of Delphi Panel members

Umberto Oscar Aguglia (Ospedali Riuniti, Reggio Calabria), Francesca Anzellotti (Ospedale SS Annunziata, Chieti), Carla Arbassino (Ospedale Salesi, Ancona), Daniela Audenino (Ospedale Galliera, Genova), Valeria Badioni (UO Università di Milano), Irene Bagnasco (Ospedale Martini, Torino), Emanuele Bartolini (Nuovo Ospedale S. Stefano, Prato), Yerma Bartolini (Ospedale Bufalini, Cesena), Vincenzo Belcastro (Ospedale S. Anna, Como), Patrizia Bergonzini (Policlinico NPI, Modena), Pia Bernardo (Univ. Della Campania Luigi Vanvitelli, Napoli), Giovanni Boero (Ospedale Centrale SS Annunziata, Taranto), Alice Bonuccelli (Ospedale Santa Chiara, Pisa), Francesco Brigo (Ospedale Tappeiner, Merano), Gaetano Cantalupo (Ospedale Maggiore Borgo Trento, Verona), Giuseppe Ceres (ASL, Salerno), Caterina Cerminara (Policlinico Tor Vergata, Roma), Valentina Chiesa (Ospedale San Paolo, Milano), Antonietta Coppola (Università Federico II, Napoli), Duccio Maria Cordelli (Policlinico Sant’Orsola, Bologna), Atilia Cozzolino (Ospedale Giuseppe Moscati, Avellino), Barbara Cruciani (Ospedale Civile, Brescia), Valentina De Giorgis (Istituto Neurologico Mondino, Pavia), Giovanni De Maria (Spedali Civili, Brescia), Fernando De Paolis (Ospedale Santa Caterina Novella, Galatina), Roberto De Simone (Policlinico Sant’Eugenio, Roma), Francesco Deleo, (IRCCS Istituto Besta, Milano), Giuseppe D’orsi (Ospedali Riuniti, Foggia), Vania Durante (pres. Brindisi Di Summa-Perrino, Brindisi), Raffaella Fagioli (Ospedale, Cona, Ferrara), Elena Frerri (IRCCS Istituto Besta, Milano), Alfonso Giordano (Univ. della Campania Luigi Vanvitelli, Napoli), Loretta Giuliano (Pres. Ospedaliero Gaspare Rodolico, Catania), Shalom Haggiag (Ospedale San Camillo, Roma), Francesca IZZI (AOU Tor Vergata, Roma), Angela La Neve (Ospedale Consorziale Policlinico, Bari), Emilio Le Piane (Ospedale Pugliese, Catanzano), Concetta Luisi (Policlinico Ospedaliero, Padova), Greta Marchior (Ospedale Civile, Gorizia), Carlo Alberto Mariani (ASP, Palermo), Carla Marini (Ospedale Salesi, Ancona), Alfonso Marrelli (Osp. Reg. S, Salvatore, L’Aquila), Marta Maschio (Center for Tumor Epilepsy, UOSD Neuroneurologia IRCCS Regina Elena, Rome), Roberto Michelucci (Ospedale Bellaria, Bologna), Fabio Minicucci (IRCCS San Raffaele, Milano), Antonio Modica (ARNAS Civico Di Cristina, Palermo), Maurizio Montalto (AO Riuniti Villa Sofia Cervello, Palermo), Francesca Muzzi (Policlinico Grassi, Ostia, Roma), Rosaria Nardello (Policlinico, Univ. Giaconne, Palermo), Alessandro Orsini (Ospedale Santa Chiara, Pisa), Nicola Pacciello (Ospedale San Carlo, Potenza), Mariangela Panebianco (Ospedale Garibaldi, Catania), Irene Pappalardo (Ospedale San Martino, Genova), Daniela Passarelli (Ospedale, Faenza, Ravenna), Giada Pauletto (Ospedale S.M. Misericordia, Udine), Piero Penza (AOU Ruggi D’Aragona, Salerno), Gabriella Perri (Ospedale Salvini Rhodense, Garbagnate, Milano), Marianna Pezzella (Ospedale Cardarelli, Napoli), Piero Pignatta (Ospedale Gradignano, Torino), Dario Pruna (AO Brotzu, Cagliari), Stefano Quadri (Ospedale Giovanni XXIII, Bergamo), Rosaria Renna (AORN Cardarelli, Napoli), Sara Renzi (Ospedale Madonna del Soccorsom, Ascoli), Paolo Ricciardelli (Ospedale, Faenza, Ravenna), Romana Rizzi (AO Santa Maria Nuova, Reggio Emilia), Angelo Russo (Ospedale Bellaria NPI, Bologna), Nicola Sciscio (Centro Australia, Avellino), Vittorio Sciricchio (Policlinico San Paolo, Bari), Carlotta Spagnoli (AO Santa Caterina Nuova, Reggio Emilia), Orazio Spitaleri (Pres. Osp. S. Marta S. Venera, Acireale, Catania), Pasquale Striano (Istituto Gaslini, Genova), Elena Tartara (Istituto Neurologico Mondino, Pavia), Lidia Urso (AO Sant’Antonio Abate, Erice, Trapani), Anna Vaudano (Ospedale, Bagiavara, Modena), Pierangelo Veggiotti (Ospedale Buzzi, Milano), Fabiana Vercellino (Ospedale San Biagio, Alessandria), Maurizio Viri (Ospedale Maggiore, Novara), Roberta Vittorini (OIRM Regina Margherita, Torino), Cristina Zammarchi (Ospedale Infermi, Rimini), Clara Zanchi (Ospedale, Seriate, Bergamo), Tiziano Zanoni (Osp. Borgo Trento, Verona), Lucia Zinno (Ospedale Maggiore, Parma), Leila Zumo (ARNAS Civico Di Caterina, Palermo), Nicoletta Foschi (Ospedale Torrette, Ancona).

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12883-021-02450-y.

Additional file 1: Supplementary Table 1. General statements and statements addressing efficacy and safety issues, with associated ratings for relevance and level of agreement. Supplementary Table 2. List of statements addressing potential implications of drug interactions, mechanism of action and adherence, with associated ratings for relevance and level of agreement. Supplementary Table 3. List of statements addressing potential implications of ease of use and other factors specific for the Italian setting, with associated ratings for relevance and level of agreement.

Acknowledgments

This project was made possible by non-conditional financial support provided by Eisai S.r.l., Milan, Italy.

Code availability

Not applicable.

Authors’ contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by PB and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Funding
Not applicable.

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
AG received speaker’s or consultancy fees from Eisai, UCB Pharma and Zogenix; BA received speaker’s or consultancy fees for projects sponsored by Eisai, Astra Zeneca, Novartis, Gilead, Sanofi, Sandoz, Sobi, MSD, Angelini, Alfasigma, Janssen, Kyowa Kirin, Abiogen, Janssen, Kyowa Kirin, Abiogen, Amgen, Teva; EP received speaker’s or consultancy fees from Eisai, Astra Zeneca, Novartis, Gilead, Sanofi, Sandoz, Sobi, MSD, Angelini, Alfasigma, Janssen, Kyowa Kirin, Abiogen, Janssen, Kyowa Kirin, Abiogen, Amgen, Teva; PB received speaker’s or consultancy fees from Arvelle, Biogen, Corlieve, Eisai, GW Pharma, Sanofi, Sun Pharma, UCB Pharma, Xenon Pharma and Zogenix; GG received speaker’s or consultancy fees from Eisai and Humana; PB received speaker’s or consultancy fees from Arvelle, Eisai, GW Pharma, LivaNova, UCB Pharma, Xenon Pharma and Zogenix.

Author details
1RICCS Eugenio Medea Scientific Institute, Epilepsy Unit, Conegliano, Via Costa Alta 37, 31015 Conegliano, TV, Italy. 2Institute of Neurology, University Magna Graecia, Catanzaro, Italy. 3RICCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy. 4Department of Biomedical and Neuroromotor Sciences, University of Bologna, Bologna, Italy. 5Cartesio solutions s.r.l, Venezia, Italy. 6Division of Clinical and Experimental Pharmacology, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. 7Department of Neuroscience, Monash University, Melbourne, Australia. 8Department of Medicine, Surgery, Odontoiatry, Medical School of Salerno, University of Salerno, Salerno, Italy.

Received: 8 August 2021 Accepted: 14 October 2021
Published: 26 October 2021

References

1. Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment in newly diagnosed epilepsy: Neurology. 2012;78:1548–54. https://doi.org/10.1212/01.wnl.0000418256.3019.

2. Beghi E, Gatti G, Tonini C, Ben-Menachem E, Chadwick DW, Nkanorovu M, et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res. 2003;57:1–13. https://doi.org/10.1016/j.eplepsyres.2003.09.007.

3. Semah F, Thomas P, Coublet S, Derambure P. Early add-on treatment vs alternative monotherapy in patients with partial epilepsies. Epileptic Disord. 2014;16:65–74. https://doi.org/10.1684/epd.2014.0650.

4. Gambardella A, Tinuper P, Accone B, Bonanni P, Coppola G, Perucca E (2021) Selection of antiseizure medications for first add-on use: a consensus paper. Epilepsy Behav. In press.

5. Njuangang S, Liyanage C, Akintoye A. Application of the Delphi technique in healthcare maintenance. Int J Health Care Qual Assur. 2017;30:737–54. https://doi.org/10.1108/IJHCQA-02-2017-0042.

6. Cretin B, Hirsch E. Adjunctive antiepileptic drugs in adult epilepsy: how the first add-on could be the last. Expert Opin Pharmacother. 2010;11:1053–67. https://doi.org/10.1517/14656561.100370975. Review.

7. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 2011;10:446–56. https://doi.org/10.1016/s1474-4422(11)70047-3 PMID: 21511198 Review.

8. Perucca P, Scheffer IE, Kiley M. The management of epilepsy in children and adults. Med J Aust. 2018;208:226–33. https://doi.org/10.5694/mja17.00951 Review.

9. Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54:1481–9. https://doi.org/10.1111/epi.12212.

10. French JA, Krauss GL, Wechsler RT, Wang XF, DiVentre B, Brandt C, et al. Perampanel for tonic-clonic seizures in idiopathic generalised epilepsy: a randomized trial. Neurology. 2015;85:950–7. https://doi.org/10.1212/ WNL.0000000000001930.

11. Krauss GL, Perucca E, Kwan P, Ben-Menachem E, Wang XF, Shih JJ, et al. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: study 307. Epilepsia. 2018;59:866–76. https://doi.org/10.1111/epi.14044.

12. Piña-Garza JE, Rosenfeld W, Saeki K, Villanueva V, Yoshinaga H, Patten A, et al. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: post hoc analysis of six randomized studies. Epilepsy Behav. 2020;104:106676. https://doi.org/10.1016/j.yebeh.2019.106676.

13. Rekter I, Krauss GL, Inoue Y, Kaneko S, Williams B, Patten A, et al. Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: analysis of four open-label extension studies. Epilepsia. 2020;61:1491–502. https://doi.org/10.1111/epi.16573.

14. Fogarasi A, Flamini R, Milh M, Phillips S, Yoshitomi S, Patten A, et al. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inappropriately controlled focal seizures or generalized tonic-clonic seizures. Epilepsia. 2020;61:125–37. https://doi.org/10.1111/epi.16413.

15. Abil Jaramillo J, Estévez Maria Jc, Grinó Úbeda JM, Vega López O, Calzado Rivas ME, Pérez Díaz H, et al. Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice. Spain prospective study (PERADON). Epilepsy Behav. 2020;102:106655. https://doi.org/10.1016/j.yebeh.2019.106655.

16. Santamarina E, Bertol V, Garayao V, García-Gomara MJ, Garamendi-Ruiz J, Giner P, et al. Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs. Seizure. 2020;83:48–56. https://doi.org/10.1016/j.seizure.2020.09.036.

17. Rootman HP, Ricker L, Heikster YA, Hulsman J, Lambrecht D, Majoie M, et al. The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure. 2009;18:327–31.

18. Rosenfeld W, Fountain NB, Kaubrys G, Ben-Menachem E, McShea C, Isjarvi J, et al. Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years. Epilepsy Behav. 2014;31:164–70. https://doi.org/10.1016/j.yebeh.2014.09.074.Clinical Trial.

19. Brandt C, Wechsler RT, O’Brien TJ, Patten A, Malhotra M, Ngo L, et al. Adjunctive perampanel and myoclonic and absence seizures: post hoc analysis of data from study 332 in patients with idiopathic generalised epilepsy. Seizure. 2020;80:115–23. https://doi.org/10.1016/j.seizure.2020.06.011.

20. Potschka H, Trinka E. Perampanel: does it have broad-spectrum potential? Epilepsia. 2019;60(Suppl 1):22–36. https://doi.org/10.1111/epi.14456.Review.

21. Lagae L. The need for broad spectrum and safe anti-epileptic drugs in childhood epilepsy. Acta Neurol Belg. 2009;109(3):167–70 Review.

22. Glausier T, Laurerzen L, Yang H, Williams B, Ma T, Fain R. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: a phase III post-hoc analysis. Epilepsia. 2016;57:19–40. https://doi.org/10.1111/epi.13114.Clinical Trial.

23. Steinhoff BJ, Patten A, Williams B, Malhotra M. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: a pooled post hoc analysis of four randomized, double-blind, phase III studies. Epilepsia. 2020;61:278–86. https://doi.org/10.1111/epi.16428. Epub 2020 Jan 16. Clinical Trial.

24. Ko D, Yang H, Williams B, Xing D, Laurerzen A. Perampanel in the treatment of partial seizures: time to onset and duration of most common adverse events from pooled phase III and extension studies. Epilepsy Behav. 2015;55:20. https://doi.org/10.1016/j.yebeh.2015.05.020.Clinical Trial.

25. Villanueva V, García M, López-González FJ, Rodríguez-Orsorio X, Toledo M, Salas-Puig J, et al. Safety, efficacy and outcome-related factors of
perampanel over 12 months in a real-world setting: the FYDATA study. Epilepsy Res. 2016;126:201–10.

26. Hasgava N, Tohyma J. Positive and negative effects of perampanel treatment on psychiatric and behavioral symptoms in adult patients with epilepsy. Epilepsy Behav. 2021;17:107515. https://doi.org/10.1016/j.yebeh.2020.107515.

27. Deleo F, Quintas R, Turner K, Didato G, Zambrelli E, Pappalardo I, et al. The impact of perampanel treatment on quality of life and psychiatric symptoms in patients with drug-resistant focal epilepsy: an observational study in Italy. Epilepsy Behav. 2019;99:106391. https://doi.org/10.1016/j.yebeh.2019.06.034.

28. Meador KJ, Yang H, Piña-Garza JE, Laerenza A, Kumar D, Weneses KA. Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial. Epilepsia. 2016;57:243–51. https://doi.org/10.1111/epi.13279 Clinical Trial.

29. Piña-Garza JE, Lagae L, Villanueva V, Renfroe JB, Laerenza A, Williams B, et al. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures. Epilepsy Behav. 2018;83:50–8. https://doi.org/10.1016/j.yebeh.2018.03.029 Clinical Trial.

30. Operto FF, Pastorino GMG, Mazza R, Di Bonaventura C, Matricardi S, Verrottì A, et al. Perampanel tolerability in children and adolescents with focal epilepsy: effects on behavior and executive functions. Epilepsy Behav. 2020;103:106679. https://doi.org/10.1016/j.yebeh.2019.106679.

31. Ahn SJ, Kim TJ, Cha KS, Jun JS, Byun JH, Shin YY, et al. Effects of perampanel on cognition and quantitative electroencephalography in patients with epilepsy. Epilepsy Behav. 2021;115:107514. https://doi.org/10.1016/j.yebeh.2020.107514.

32. Rocamora R, Álvarez I, Chavarría B, Principe A. Perampanel effect on sleep architecture in patients with epilepsy. Seizure. 2020;76:137–42. https://doi.org/10.1016/j.seizure.2020.01.021.

33. Yang H, Laerenza L, Williams B, Patten A, Hussein Z, Ferry J. Lack of effect of perampanel on QT interval duration: results from a thorough QT analysis and pooled partial seizure phase III clinical trials. Epilepsy Res. 2015;114:122–30. https://doi.org/10.1016/j.eplseyres.2015.04.010 Clinical Trial.

34. Vázquez B, Tomson T, Dobrinsky C, Schuck E, O’Brien TJ. Perampanel and pregnancy. Epilepsia. 2021;62:698–708. https://doi.org/10.1111/epi.16821.

35. Franco V, Crema F, Judice A, Zaccara G, Grillo E. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res. 2013;70:35–40. https://doi.org/10.1016/j.phrs.2012.12.006.

36. Gidal BE, Ferry J, Majid O, Hussein Z. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia. 2013;54:1490–7. https://doi.org/10.1111/epi.12240.

37. Gidal BE, Laerenza A, Hussein Z, Yang H, Fain R, Edelstein J, et al. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology. 2015;84:1972–80. https://doi.org/10.1212/WNL.0000000000000306.

38. Villanueva V, Majid O, Nabanchang C, Yang H, Laerenza A, Ferry J, et al. Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures. Epilepsia Res. 2016;127:126–34. https://doi.org/10.1016/j.eplseyres.2016.08.025 Clinical Trial.

39. European Medicines Agency (EMA). Perampanel (Fycompa): Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/fycompa-esar-product-information_en.pdf (Last Accessed 1 Oct 2021).

40. Food and Drug Administration. Fycompa – Full Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202834d016b.208277u048b.pdf (Last Accessed 1 Oct 2021).

41. Villanueva V, Montoya J, Castilla A, Mauri-Llerda JA, Giner P, López-González FJ, et al. Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12-month GENERAL study. Epilepsia. 2018;59:1740–52. https://doi.org/10.1111/epi.14522.

42. Di Bonaventura C, Labate A, Maschio M, Meletti S, Russo E. AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives. Expert Opin Pharmacother. 2017;18:1751–64. https://doi.org/10.1080/14656566.2017.1392509.

43. Deckers CL, Czauczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 2000;41:1364–74. https://doi.org/10.1111/j.1528-1157.2000.tb00111.x.

44. Brodie MJ, Covianis A, Gil-Nagel A, Lercie H, Perucca E, Sills GJ, et al. Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav. 2011;21:331–41. https://doi.org/10.1016/j.yebeh.2011.05.025.

45. Perucca E. The pharmacology of new antiepileptic drugs: does a novel mechanism of action really matter? CNS Drugs. 2011;25:907–12. https://doi.org/10.2165/11589000000000000000.

46. Verrottì A, Lattanzi S, Brizzo F, Zaccara G. Pharmacodynamic interactions of antiepileptic drugs: from bench to clinical practice. Epilepsy Behav. 2020;104:106939. https://doi.org/10.1016/j.yebeh.2020.106939.

47. Suzuki H, Michini N, Ohnishi H, Yokoyama R, Enatsu R, Ochi S. Forgetting to take antiseizure medications is associated with focal to bilateral tonic-clonic seizures, as revealed by a cross-sectional study. PLoS One. 2020;15:e0240082. https://doi.org/10.1371/journal.pone.0240082.

48. Faught E, Duh MS, Weiner JR, Guérin A, Cunnington MC. Nonadherence to antiepileptic drugs and increased mortality: findings from the RAN SOM study. Neurology. 2008;71:1572–8. https://doi.org/10.1212/01.wnl.0000319693.10338.b9.

49. Sveinsson O, Andersson S, Mattsson P, Carlsson S, Tomson T. Pharmacologic treatment and SUDEP risk: a nationwide, population-based, case-control study. Neurology. 2020;95:e2509–18. https://doi.org/10.1212/WNL.0000000000010874.

50. Efanov J, Baker GA. Managing patient adherence and quality of life in epilepsy. Neuropsychiatr Dis Treat. 2007;3:117–31. https://doi.org/10.2147/ndt.2007.3.11.17.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

Learn more: biomedcentral.com/submissions

At BMC, research is always in progress.